MJR PharmJet GmbH


6,8€ Million Granted to nTRACK Horizon 2020 Project Designed to Study Multimodal Nanoparticles for Muscle Regeneration

Grant from European Union’s Horizon 2020 programme to nTRACK project designed to study multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration

The European Union has awarded a grant of 6,8 million Euro to nTRACK collaborative project. The grant, from the Horizon 2020 framework programme, was awarded to nTRACK, a research and innovation project carried out by an international consortium led by LEITAT. The project partners are: MJR PharmJet, Bar Ilan University, Pluristem Therapeutics, University of Mainz, BET Solutions, National Centre for Scientific Research “Demokritos”, Vall d'Hebron Research Institute, Vivotecnia Research, RIVM, Asphalion, and Cambridge Nanomaterials Technology. The project will officially be launched on the 16th of October in Barcelona.

Press release nTrack Horizon 2020 Project

MJR PharmJet participates in the European research project “N2B-Patch” project financed by the European Commision for the call “H2020-NMBP: CALL FOR NANOTECHNOLOGIES, ADVANCED MATERIALS, BIOTECHNOLOGY AND PRODUCTION” program. The N2B-Patch project brings Universities, Research institutes, SMEs and Industry with complementary distinct expertise out of chemical, biological, regulatory and business areas. Project aims to  develop a new innovative nose to brain drug delivery technology based on the synthesis of a biomaterial-based innovative galenic formulation that will be applied with the aid of a novel medical device equipped with a container closure system as a hydrogel patch to the nasal olfactory region for the chronic treatment of MS. 

Click here for N2B-Patch press release


MJR PharmJet has been shortlisted as finalist in the category 4. Manufacturing Technology and Equipment" in the CPhI Pharma Awards 2017!

For more information: http://awards.cphi.com/finalists

MJR PharmJet`s  Soapbox application has been accepted for presentation at the 2015 CRS Annual Meeting & Exposition held in Edinburgh, Scotland. Soapbox sessions of the Annual CRS Meetings are well-attended, highly interactive part of the program giving an opportunity companies to present new ideas, products and services. CRS official website reports that Soapbox sessions attract attendees from “Big Pharma, biotechs, product formulators, licensing officers, venture capitalists, technology transfer offices, universities—in essence, anyone and everyone who has an interest in exploring the hottest innovations and tools”. MJR PharmJet was selected among a huge number of applicants with proposed presentation titled “ Microjet Reactor Technology for Continuous Nanoparticle Production under Controlled Conditions”. 

The European Commission grants “npSCOPE” project bringing together nine partners including MJR PharmJet to develop a new integrated instrument for accurate and reproducible physicochemical characterisation of nanoparticles as part of the “H2020-NMBP: CALL FOR NANOTECHNOLOGIES, ADVANCED MATERIALS, BIOTECHNOLOGY AND PRODUCTION” program. The npSCOPE project aims at developing a new integrated instrument (the nanoparticle-scope) optimised for providing a complete physico-chemical characterisation of nanoparticles both in their pristine form or embedded in complex matrices such as biological tissues. Using sophisticated correlative data processing methodologies and algorithms based on statistical methods in conjunction with appropriate visualisation methods of the results, the npSCOPE instrument will allow rapid, accurate and reproducible measurements.

For more information: www.npscope.eu/

CPhI Worldwide, organised by UBM Live, announced the winners of the 11th annual CPhI live Pharma Awards. The annual awards showcase outstanding developments and innovations from the pharma industry's most dynamic and progressive players. Open to the entire pharma industry, the awards honour companies that are driving the industry forward with thought leadership, unveiling top pharma innovators to global trade. In addition to returning annual award categories for 'Formulation', 'Process Development' and 'Packaging', a new category recognising 'Innovation in Partnering' debuts this year. Supported by Pharmaceutical Outsourcing magazine, this award honours partnering methods, use of technology, unexpected outcomes and unique partnering practices.

The awards panel deliberated for several hours over the impressive list of entries, before coming to the unanimous decision, selecting MJR PharmJet in the Formulation category:

By forming counter-ion complexes, the solubility of the API can be improved without chemically altering it, allowing nanoparticles with an enhanced load to be formed via the company's microjet technology. The principle has been proved via a formulation of the drug ciprofloxacin for cystic fibrosis patients, creating a nanodelivery system that allows the drug to penetrate the thick mucus that forms in their lungs. The employed technology can be applied to a wide range of molecules and different markets, including nutraceuticals and cosmetics.